Brief: IMDX Enrolls First Patient In Graftassuredx Clinical Trial And Welcomes New Hospital Participants
08/09/2025 12:32
Sept 8 (Reuters) - Insight Molecular Diagnostics Inc IMDX.O: IMDX ENROLLS FIRST PATIENT IN GRAFTASSUREDX CLINICAL TRIAL AND WELCOMES NEW HOSPITAL PARTICIPANTS INSIGHT MOLECULAR DIAGNOSTICS INC - GRAFTASSUREDX ON TRACK FOR FDA SUBMISSION BY END OF 2025 Source text: ID:nGNX3487ZK Further company coverage: IMDX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission